
Tay Therapeutics in licensing deal with VYNE Therapeutics
Tay Therapeutics Ltd’s exclusive license deal with VYNE Therapeutics Inc. on the oral BET inhibitor, TAY-B2 (now known as VYN201) forsees an upfront...

Swiss Biotech Report: Sunrise, not sunset, is the feeling of the hour
The latest Swiss Biotech Report, published at the end of April by the Swiss Biotech Association (SBA) in collaboration with EY and eight other...

Algal enzyme synthesizes gasoline building blocks
Deciphering the mechanism of the photoenzyme Fatty acid photodecarboxylase (FAP), a research team co-headed by Frederic Beisson from University...

Pfizer-Seagen: Acquisition in the works
As announced earlier this week, Pfizer Inc. plans to purchase Seagen for US$43bn. The Boards of Directors of both companies approved the transaction...

Neurodegenerative disorders are being fought with €28m
The Danish biotech Teitur Trophics ApS, aiming to treat chronic neurological disorders, has completed a €28m Series A funding. With the money, Teitur...

Mosaic Therapeutics closes $28m series A financing
Oncology specialist Mosaic Therapeutics Ltd will use a $28m financing to push its preclinical pipeline of targeted oncology therapies for...

Upscaling AAV gene therapy
Mid-March marks the start of the collaboration of Remedium Bio Inc. and Biovial Oy on an AAV gene therapy for osteoarthritis. Rheumatology and...